Cell and Gene Therapies (CGTs) have emerged as one of the fastest growing sectors within the Life Sciences industry. CGTs hold the promise of treating or even curing some cancers and rare diseases. These emerging therapies are very expensive—often between $400,000 and $2 million per dose. CGT market is expected to nearly quadruple over the next five years—from $5.3 billion in 2022 to $19.9 billion by 2027.
2022 was a record year for the approval of never-before-authorized gene therapies, with three new therapies approved to treat rare diseases and another approved to treat bladder cancer. Also, five therapies already approved in the US or Europe were authorized for the first time in a new geography or another indication. This is just the tip of the iceberg- 13 brand new CGTs could be approved for use in the US, Europe, or both by the end of 2023. We are in reach of the FDA’s often-cited 2019 prediction that by 2025 it would approve 10-20 new CGTs a year.
CGT value chain is more complex than traditional pharma, requiring more stakeholders and touchpoints. This whitepaper provides a comprehensive overview of the rapidly evolving field of cell and gene therapy. It also explores how CGTs will transform healthcare in the next 10 years. Read the whitepaper and delve into:
- Basic understanding of Cell and Gene Therapies – both Autologous and Allogeneic
- CGT value chain and how it is different from traditional pharma
- Expedited programs to accelerate the launch of CGTs
- Major challenges of commercializing CGTs
- How to prepare for a successful launch
- Hexaware’s experience across the CGT value chain
Uncover the rapid growth, challenges, and transformative capabilities of CGTs in this whitepaper.
